Silexion Therapeutics Files 8-K
Ticker: SLXNW · Form: 8-K · Filed: Sep 30, 2025 · CIK: 2022416
Sentiment: neutral
Topics: corporate-filing, regulation-fd, financial-statements
Related Tickers: SLXN
TL;DR
Silexion Therapeutics filed an 8-K on 9/30/25, former name Biomotion Sciences.
AI Summary
Silexion Therapeutics Corp. filed an 8-K on September 30, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, formerly known as Biomotion Sciences until May 6, 2024, is incorporated in the Cayman Islands and headquartered in Ramat-Gan, Israel.
Why It Matters
This filing provides an update on Silexion Therapeutics Corp.'s regulatory and financial disclosures, which is important for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a routine filing for corporate information and does not appear to contain significant new risks.
Key Players & Entities
- Silexion Therapeutics Corp (company) — Registrant
- Biomotion Sciences (company) — Former Company Name
- September 30, 2025 (date) — Report Date
- May 6, 2024 (date) — Date of Name Change
- Cayman Islands (jurisdiction) — State of Incorporation
- Ramat-Gan, Israel (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
When was Silexion Therapeutics Corp. previously known by another name?
Silexion Therapeutics Corp. was formerly known as Biomotion Sciences until May 6, 2024.
Where are Silexion Therapeutics Corp.'s principal executive offices located?
Silexion Therapeutics Corp.'s principal executive offices are located at 12 Abba Hillel Road, Ramat-Gan, Israel.
What is the state of incorporation for Silexion Therapeutics Corp?
Silexion Therapeutics Corp. is incorporated in the Cayman Islands.
What is the SIC code for Silexion Therapeutics Corp?
The Standard Industrial Classification (SIC) code for Silexion Therapeutics Corp. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 548 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2025-09-30 09:05:56
Key Financial Figures
- $0.0135 — registered Ordinary Shares, par value $0.0135 per share SLXN The Nasdaq Stock Mar
- $1,552.50 — Ordinary Shares at an exercise price of $1,552.50 per share SLXNW The Nasdaq Stock Ma
Filing Documents
- zk2533822.htm (8-K) — 49KB
- exhibit_99-1.htm (EX-99.1) — 21KB
- image00001.jpg (GRAPHIC) — 27KB
- 0001178913-25-003444.txt ( ) — 284KB
- slxn-20250930.xsd (EX-101.SCH) — 5KB
- slxn-20250930_def.xml (EX-101.DEF) — 18KB
- slxn-20250930_lab.xml (EX-101.LAB) — 27KB
- slxn-20250930_pre.xml (EX-101.PRE) — 20KB
- zk2533822_htm.xml (XML) — 6KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 30, 2025, Silexion Therapeutics Corp issued a press release entitled "Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer " A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference. The information in Item 7.01 of this Form 8-K, including the information in the press release furnished pursuant to this Item 7.01 of Form 8-K, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Form 8-K, including the information in the press release, shall not be deemed to be incorporated by reference in the filings of the registrant under the Securities Act of 1933, as amended.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits 99.1 Press Release dated September 30, 2025 104 Cover Page Interactive Data File (formatted in Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILEXION THERAPEUTICS CORP Date: September 30, 2025 /s/ Ilan Hadar Name: Ilan Hadar Title: Chief Executive Officer